Hypercholesterolemia - Pipeline Review, H1 2017

  • ID: 4284816
  • Report
  • 197 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 3SBio Inc
  • ARMO Biosciences Inc
  • Daewon Pharm Co Ltd
  • Gemphire Therapeutics Inc
  • Leading BioSciences Inc
  • Pfizer Inc
  • MORE
Hypercholesterolemia - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Hypercholesterolemia - Pipeline Review, H1 2017, provides an overview of the Hypercholesterolemia (Metabolic Disorders) pipeline landscape.

Hypercholesterolemia arises due to high levels of cholesterol in the blood. These abnormal levels may lead to various diseases especially cardiovascular diseases. Cholesterol deposit in the arteries and may cause the narrowing of blood vessels hence restricting the blood flow. The predisposing factors for hypercholesterolemia include various diseases such as diabetes mellitus, renal diseases, obesity etc. The other factors involved are heredity, certain drugs, sedentary lifestyle, smoking, alcoholism, stress and high fat diet. The symptoms for hypercholesterolemia include blocked arteries, leg pain, chest pain and cholesterol deposits. The disease can be controlled by lifestyle changes, dietary changes, and medications.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Hypercholesterolemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hypercholesterolemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypercholesterolemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypercholesterolemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 11, 14, 3, 1, 1, 20, 7 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 2 molecules, respectively.

Hypercholesterolemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypercholesterolemia (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Hypercholesterolemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hypercholesterolemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hypercholesterolemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hypercholesterolemia (Metabolic Disorders)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hypercholesterolemia (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hypercholesterolemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 3SBio Inc
  • ARMO Biosciences Inc
  • Daewon Pharm Co Ltd
  • Gemphire Therapeutics Inc
  • Leading BioSciences Inc
  • Pfizer Inc
  • MORE
Introduction

Hypercholesterolemia - Overview

Hypercholesterolemia - Therapeutics Development

Hypercholesterolemia - Therapeutics Assessment

Hypercholesterolemia - Companies Involved in Therapeutics Development

Hypercholesterolemia - Drug Profiles

Hypercholesterolemia - Dormant Projects

Hypercholesterolemia - Discontinued Products

Hypercholesterolemia - Product Development Milestones

Appendix

List of Tables:

Number of Products under Development for Hypercholesterolemia, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Companies, H1 2017 (Contd..1), H1

Number of Products under Development by Companies, H1 2017 (Contd..2), H1

Number of Products under Development by Universities/Institutes, H1

Products under Development by Companies, H1

Products under Development by Companies, H1 2017 (Contd..1), H1

Products under Development by Companies, H1 2017 (Contd..2), H1

Products under Development by Companies, H1 2017 (Contd..3), H1

Products under Development by Universities/Institutes, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Target, H1 2017 (Contd..1), H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Hypercholesterolemia - Pipeline by 3SBio Inc, H1

Hypercholesterolemia - Pipeline by AFFiRiS AG, H1

Hypercholesterolemia - Pipeline by Akcea Therapeutics Inc, H1

Hypercholesterolemia - Pipeline by Alvogen Korea Co Ltd, H1

Hypercholesterolemia - Pipeline by ARMO Biosciences Inc, H1

Hypercholesterolemia - Pipeline by AstraZeneca Plc, H1

Hypercholesterolemia - Pipeline by BioLingus AG, H1

Hypercholesterolemia - Pipeline by Catabasis Pharmaceuticals Inc, H1

Hypercholesterolemia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1

Hypercholesterolemia - Pipeline by CymaBay Therapeutics Inc, H1

Hypercholesterolemia - Pipeline by Daewon Pharm Co Ltd, H1

Hypercholesterolemia - Pipeline by Daewoong Co Ltd, H1

Hypercholesterolemia - Pipeline by Dicerna Pharmaceuticals Inc, H1

Hypercholesterolemia - Pipeline by Dybly AG, H1

Hypercholesterolemia - Pipeline by Esperion Therapeutics Inc, H1

Hypercholesterolemia - Pipeline by Gemphire Therapeutics Inc, H1

Hypercholesterolemia - Pipeline by Golden Biotechnology Corp, H1

Hypercholesterolemia - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1

Hypercholesterolemia - Pipeline by Immune Response BioPharma Inc, H1

Hypercholesterolemia - Pipeline by Johnson & Johnson, H1

Hypercholesterolemia - Pipeline by Kadmon Corp LLC, H1

Hypercholesterolemia - Pipeline by Kyorin Pharmaceutical Co Ltd, H1

Hypercholesterolemia - Pipeline by Leading BioSciences Inc, H1

Hypercholesterolemia - Pipeline by LipimetiX Development Inc, H1

Hypercholesterolemia - Pipeline by Lotus Pharmaceutical Co Ltd, H1

Hypercholesterolemia - Pipeline by Medlab Clinical Ltd, H1

Hypercholesterolemia - Pipeline by Merck & Co Inc, H1

Hypercholesterolemia - Pipeline by Pfizer Inc, H1

Hypercholesterolemia - Pipeline by Planet Biotechnology Inc, H1

Hypercholesterolemia - Pipeline by Progenra Inc, H1

Hypercholesterolemia - Pipeline by Regeneron Pharmaceuticals Inc, H1

Hypercholesterolemia - Pipeline by RegenxBio Inc, H1

Hypercholesterolemia - Pipeline by Serometrix LLC, H1

Hypercholesterolemia - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1

Hypercholesterolemia - Pipeline by Solvotrin Therapeutics Ltd, H1

Hypercholesterolemia - Pipeline by The Medicines Company, H1

Hypercholesterolemia - Pipeline by Viking Therapeutics Inc, H1

Hypercholesterolemia - Dormant Projects, H1

Hypercholesterolemia - Dormant Projects, H1 2017 (Contd..1), H1

Hypercholesterolemia - Dormant Projects, H1 2017 (Contd..2), H1

Hypercholesterolemia - Dormant Projects, H1 2017 (Contd..3), H1

Hypercholesterolemia - Discontinued Products, H1

List of Figures:

Number of Products under Development for Hypercholesterolemia, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Number of Products by Top 10 Targets, H1

Number of Products by Stage and Top 10 Targets, H1

Number of Products by Top 10 Mechanism of Actions, H1

Number of Products by Stage and Top 10 Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 3SBio Inc
  • AFFiRiS AG
  • Akcea Therapeutics Inc
  • Alvogen Korea Co Ltd
  • ARMO Biosciences Inc
  • AstraZeneca Plc
  • BioLingus AG
  • Catabasis Pharmaceuticals Inc
  • Chong Kun Dang Pharmaceutical Corp
  • CymaBay Therapeutics Inc
  • Daewon Pharm Co Ltd
  • Daewoong Co Ltd
  • Dicerna Pharmaceuticals Inc
  • Dybly AG
  • Esperion Therapeutics Inc
  • Gemphire Therapeutics Inc
  • Golden Biotechnology Corp
  • Hanmi Pharmaceuticals Co Ltd
  • Immune Response BioPharma Inc
  • Johnson & Johnson
  • Kadmon Corp LLC
  • Kyorin Pharmaceutical Co Ltd
  • Leading BioSciences Inc
  • LipimetiX Development Inc
  • Lotus Pharmaceutical Co Ltd
  • Medlab Clinical Ltd
  • Merck & Co Inc
  • Pfizer Inc
  • Planet Biotechnology Inc
  • Progenra Inc
  • Regeneron Pharmaceuticals Inc
  • RegenxBio Inc
  • Serometrix LLC
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
  • Solvotrin Therapeutics Ltd
  • The Medicines Company
  • Viking Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll